Suspension of trading
Valuation Merrimack Pharmaceuticals
Stocks
MACK
US5903282094
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2024-05-17 EDT
|
5-day change | 1st Jan Change | ||
| 15.13 USD | -0.13% |
|
-.--% | - |
| 24-05-20 | Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index | CI |
| 24-05-20 | Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index | CI |
Company Valuation: Merrimack Pharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 51.5 | 42.09 | 92.19 | 52.43 | 153.7 | 192 |
| Change | - | -18.27% | 119.01% | -43.12% | 193.09% | 24.96% |
| Enterprise Value (EV) 1 | -4.902 | 25.51 | 78.15 | 38.23 | 134.2 | 173.2 |
| Change | - | 620.48% | 206.32% | -51.08% | 251.13% | 29% |
| P/E | -1.27x | -2.43x | -30.4x | -21.4x | -100x | -162x |
| PBR | 0.88x | 2.43x | 5.76x | 3.7x | 8.46x | 10.3x |
| PEG | - | 0x | 0.4x | 1.1x | 2.7x | 5.9x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | 0.08x | -1.26x | -28.1x | - | - | - |
| EV / EBIT | 0.08x | -1.14x | -15.6x | -14.6x | -61.7x | -79.6x |
| EV / FCF | 0.12x | -1.57x | -46.9x | 52.8x | -185x | -153x |
| FCF Yield | 856% | -63.5% | -2.13% | 1.89% | -0.54% | -0.65% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -3.036 | -1.298 | -0.2263 | -0.1831 | -0.1142 | -0.0826 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -60.2 | -20.24 | -2.784 | - | - | - |
| EBIT 1 | -64.28 | -22.47 | -5.012 | -2.616 | -2.174 | -2.176 |
| Net income 1 | -40.51 | -17.33 | -3.028 | -2.455 | -1.544 | -1.181 |
| Net Debt 1 | -56.4 | -16.58 | -14.04 | -14.2 | -19.44 | -18.88 |
| Reference price 2 | 3.86 | 3.15 | 6.89 | 3.91 | 11.46 | 13.41 |
| Nbr of stocks (in thousands) | 13,343 | 13,363 | 13,380 | 13,410 | 13,410 | 14,321 |
| Announcement Date | 3/6/19 | 3/12/20 | 3/10/21 | 3/9/22 | 3/9/23 | 3/7/24 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 224M | |
| 31.44x | 5.66x | 16.96x | 1.03% | 46.38B | |
| -21.25x | 245.77x | -22.82x | -.--% | 44.51B | |
| 33.09x | 3.22x | 13.91x | -.--% | 42.3B | |
| 45.98x | 5.31x | 29.05x | -.--% | 39.91B | |
| 27.78x | 8.36x | 21.2x | 0.41% | 32.79B | |
| 33.34x | 5.46x | 24.79x | -.--% | 16.36B | |
| 23.65x | 2.07x | 8.96x | 1.13% | 14.31B | |
| 74.46x | 3.94x | 15.27x | -.--% | 13.29B | |
| Average | 31.06x | 34.97x | 13.42x | 0.32% | 27.79B | |
| Weighted average by Cap. | 26.14x | 48.01x | 11.81x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MACK Stock
- Valuation Merrimack Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
